Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of neoadjuvant DCF with pegfilgrastim day 3 in esophageal cancer
jRCTs041190129Completed
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegfilgrastim in esophageal cancer. Primary endpoint: Rate of febrile neutropenia. Started Mar 2020; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs041190129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190129.